AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1396198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole 2G (Naxogin Farmitalia Carlo Erba, Italy)
Number of subjects: 72
Study 1396198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole 4G in two equally divided doses 24 hours apart (2GBD)
Number of subjects: 72
Study 1396198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole 3G
Number of subjects: 72
Study 1396198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2G (Fasigyn, Pfizer Ltd)
Number of subjects: 72
Study 1396198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole 1.5G (Tiberal, Roche, Switzerland)
Number of subjects: 72
Study 1396198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole 2GBD
Number of subjects: 72
Study 2868495 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 60
Study 2868495 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60
Study 2868495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29843659 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossroads‐II study intervention involving a face to face household survey and additional questionnaires and biophysical measurements.
Number of subjects: 3600
Study 29843659 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossroads‐II study intervention with a composite measure of health service access.
Number of subjects: 3600
Study 27118042 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education with poster reminder intervention
Number of subjects: 564
Study 27118042 — intervention group
Group type: COMPARATOR
Intervention: Control group (posttest only)
Number of subjects: 564
Study 24831919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (BG: 70‐110 mg/dL)
Number of subjects: 93
Study 24831919 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control (BG: 70‐180 mg/dL)
Number of subjects: 93
Study 24831919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 93
Study 22277266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Quixil)
Number of subjects: 40
Study 19644691 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) program and exercises
Number of subjects: 59
Study 19644691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment and exercises
Number of subjects: 59
Study 19644691 — intervention group
Group type: COMPARATOR
Intervention: Control group (only exercises)
Number of subjects: 59
Study 18483859 — intervention group
Group type: EXPERIMENTAL
Intervention: Televised training with limited technical assistance
Number of subjects: 24
Study 18483859 — intervention group
Group type: EXPERIMENTAL
Intervention: Televised training alone
Number of subjects: 24
Study 18483859 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 16008114 — intervention group
Group type: EXPERIMENTAL
Intervention: Korodin (25 drops, applied once, followed by daily 3 x 25 drops for 7 days)
Number of subjects: 39
Study 16008114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single application and daily treatment for 7 days)
Number of subjects: 39
Study 12145174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet and exercise group
Number of subjects: 522
Study 12145174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 12145174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala12 allele
Number of subjects: 522
Study 10368079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OCBZ) 1,200 mg/day
Number of subjects: 22
Study 10368079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7729443 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training (24 sessions)
Number of subjects: 34
Study 7729443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 34
Study 7729443 — intervention group
Group type: EXPERIMENTAL
Intervention: High HRV group (n = 5)
Number of subjects: 34
Study 7729443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HRV group (n = 5)
Number of subjects: 34
Study 1970226 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 9
Study 1970226 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg
Number of subjects: 9
Study 1970226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7315901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis
Number of subjects: 386
Study 7315901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 29023649 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual individuation training
Number of subjects: 95
Study 29114894 — intervention group
Group type: EXPERIMENTAL
Intervention: INCS plus montelukast for 1 year
Number of subjects: 72
Study 29114894 — intervention group
Group type: COMPARATOR
Intervention: INCS in monotherapy
Number of subjects: 72
Study 26575323 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg salmeterol treatment
Number of subjects: 10
Study 26575323 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg salmeterol treatment
Number of subjects: 10
Study 23860881 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM autoantibodies against phosphorylcholine (anti-PC)
Number of subjects: 3356
Study 22581070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 107
Study 22581070 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional adaptation skills training
Number of subjects: 107
Study 22581070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (cognitive remediation + functional skills training)
Number of subjects: 107
Study 22581070 — intervention group
Group type: COMPARATOR
Intervention: Cognitive remediation alone
Number of subjects: 107
Study 22581070 — intervention group
Group type: COMPARATOR
Intervention: Functional skills training
Number of subjects: 107
Study 20875883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 140
Study 20875883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 18590350 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-828L (800 mg daily for 56 days)
Number of subjects: 26
Study 18590350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 26
Study 15708732 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous VaD group
Number of subjects: 0
Study 15708732 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical infarct or SH-only subtype
Number of subjects: 0
Study 15708732 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphometric changes (increased subcortical hyperintensities, decreased whole brain volume)
Number of subjects: 0
Study 14628497 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen supplementation therapy (testosterone replacement therapy)
Number of subjects: 0
Study 10029210 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive Compulsive Drinking Scale (OCDS)
Number of subjects: 127
Study 10029210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption factor from OCDS
Number of subjects: 127
Study 8674328 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous Arterial blood Management Protection system (VAMP)
Number of subjects: 40
Study 8674328 — intervention group
Group type: COMPARATOR
Intervention: Safe Draw
Number of subjects: 40
Study 1914031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheum E
Number of subjects: 30
Study 1914031 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 30
Study 1914031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheum E + Captopril
Number of subjects: 30
Study 1914031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheum E (in 5/6 nephrectomized rats)
Number of subjects: 30
Study 6854550 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl, Norlestrin, Ovral (first study)
Number of subjects: 0
Study 6854550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brevicon, Lo-Ovral (second study)
Number of subjects: 0
Study 31560131 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual pads for 6 months
Number of subjects: 240
Study 31560131 — intervention group
Group type: COMPARATOR
Intervention: No pads (control group)
Number of subjects: 240
Study 31539329 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Video Interview (SVI) score
Number of subjects: 321
Study 31539329 — intervention group
Group type: COMPARATOR
Intervention: Traditional Interview (TI) score
Number of subjects: 321
Study 27781372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet 30 mcg (SST)
Number of subjects: 161
Study 27781372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 24627339 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (1 mg capsule)
Number of subjects: 0
Study 24627339 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (1 mg capsule)
Number of subjects: 0
Study 25263017 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with eGFR <30 mL/min
Number of subjects: 5710
Study 25263017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall VTE patients
Number of subjects: 5710
Study 25263017 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE patients with renal impairment
Number of subjects: 5710
Study 25263017 — intervention group
Group type: COMPARATOR
Intervention: VTE patients with eGFR >90 mL/min
Number of subjects: 5710
Study 25263017 — intervention group
Group type: COMPARATOR
Intervention: VTE patients with eGFR 60-89 mL/min
Number of subjects: 5710
Study 25263017 — intervention group
Group type: COMPARATOR
Intervention: VTE patients with eGFR 45-59 mL/min
Number of subjects: 5710
Study 25263017 — intervention group
Group type: COMPARATOR
Intervention: VTE patients with eGFR 30-44 mL/min
Number of subjects: 5710
Study 25263017 — intervention group
Group type: COMPARATOR
Intervention: VTE patients with eGFR 15-29 mL/min
Number of subjects: 5710
Study 25263017 — intervention group
Group type: COMPARATOR
Intervention: VTE patients with end-stage renal disease
Number of subjects: 5710
Study 22846608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniff nasal inspiratory pressure (SNIP) in sitting position (SNIPsitt)
Number of subjects: 20
Study 22846608 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced vital capacity (FVC)
Number of subjects: 20
Study 22846608 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS functional rating scale score (ALSFRS-R)
Number of subjects: 20
Study 22846608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniff nasal inspiratory pressure (SNIP) in supine position (SNIPsup)
Number of subjects: 20
Study 19202330 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin therapy (folic acid 2 mg, vitamin B(6) 25 mg, vitamin B(12) 0.5 mg)
Number of subjects: 30
Study 19202330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17319775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 21
Study 17319775 — intervention group
Group type: COMPARATOR
Intervention: Electric toothbrush
Number of subjects: 21
Study 17319775 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 21
Study 15247115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine hydrochloride
Number of subjects: 166
Study 15247115 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine hydrochloride
Number of subjects: 166
Study 15247115 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine hydrochloride
Number of subjects: 166
Study 15247115 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 166
Study 11100387 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress at 44 degrees C
Number of subjects: 28
Study 8968264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 874
Study 8968264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 1535578 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily
Number of subjects: 200
Study 1535578 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg b.i.d.
Number of subjects: 200
Study 6367784 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg intravenously followed by 200 mg daily for three months)
Number of subjects: 1395
Study 6367784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 6367784 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study 31235169 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention provided by pharmaceutics students
Number of subjects: 171
Study 31235169 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 171
Study 30049498 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tailored education group (n=35)
Number of subjects: 120
Study 30049498 — intervention group
Group type: COMPARATOR
Intervention: Standard care group with online access (n=36)
Number of subjects: 120
Study 30049498 — intervention group
Group type: COMPARATOR
Intervention: Standard care group without computer/tablet/smartphone (n=49)
Number of subjects: 120
Study 26220357 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral 8 Fr subclavian vein sheaths
Number of subjects: 61
Study 26220357 — intervention group
Group type: COMPARATOR
Intervention: 16 Fr percutaneous superior vena cava cannula
Number of subjects: 61
Study 26220357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 23112075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricot compression bandage plus intermittent cryocompression therapy 15 times for 30 minutes
Number of subjects: 30
Study 23112075 — intervention group
Group type: COMPARATOR
Intervention: Tricot compression bandage alone
Number of subjects: 30
Study 20105043 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial insulin (PPI) (Exubera)
Number of subjects: 257
Study 20105043 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin (BI) (insulin glargine)
Number of subjects: 257
Study 20105043 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial insulin (PPI)
Number of subjects: 257
Study 20105043 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin (BI)
Number of subjects: 257
Study 18619998 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measurements by doctors (weight, height, BMI, waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR))
Number of subjects: 24
Study 18619998 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measurements after a one-hour training session
Number of subjects: 24
Study 15851890 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg EREM
Number of subjects: 200
Study 15851890 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg EREM
Number of subjects: 200
Study 15851890 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg EREM
Number of subjects: 200
Study 15851890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 14594344 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 20 mg
Number of subjects: 45
Study 14594344 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg
Number of subjects: 45
Study 14594344 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 80 mg
Number of subjects: 45
Study 14594344 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline-corrected testosterone values
Number of subjects: 45
Study 14594344 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of testosterone undecanoate
Number of subjects: 45
Study 10827390 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflenapent emulsion
Number of subjects: 280
Study 10827390 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 280
Study 8794420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% all‐trans‐retinoic acid (tretinoin)
Number of subjects: 0
Study 8794420 — intervention group
Group type: COMPARATOR
Intervention: 6% glycolic acid
Number of subjects: 0
Study 1379860 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuanxiong
Number of subjects: 220
Study 1379860 — intervention group
Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 220
Study 3900303 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide alone (1.0 to 3.0 mg/kg)
Number of subjects: 18
Study 3900303 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide with adjunct dexamethasone (20 mg) at a fixed dose of 2.0 mg/kg
Number of subjects: 18
Study 3900303 — intervention group
Group type: COMPARATOR
Intervention: Control group (metoclopramide without dexamethasone)
Number of subjects: 18
Study 31272393 — intervention group
Group type: EXPERIMENTAL
Intervention: Promised HK$100 incentive upon completion
Number of subjects: 1246
Study 31272393 — intervention group
Group type: EXPERIMENTAL
Intervention: Promised HK$200 incentive upon completion
Number of subjects: 1246
Study 31272393 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid HK$100 incentive plus another promised HK$100 incentive (mixed incentive)
Number of subjects: 1246
Study 31272393 — intervention group
Group type: COMPARATOR
Intervention: No incentive (control group)
Number of subjects: 1246
Study 29197867 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical coconut oil (5 mL/kg) twice daily for 21 days
Number of subjects: 72
Study 29197867 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 72
Study 29197867 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical coconut oil
Number of subjects: 72
Study 27054908 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2mA, 20min)
Number of subjects: 0
Study 27054908 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS (2mA, 20min)
Number of subjects: 0
Study 27054908 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent Anodal tDCS after Cathodal tDCS
Number of subjects: 0
Study 24576202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.50% (50 mL)
Number of subjects: 37
Study 24576202 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 37
Study 23027801 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-consistent warfarin dosing
Number of subjects: 6022
Study 20544135 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated CVC
Number of subjects: 172
Study 20544135 — intervention group
Group type: COMPARATOR
Intervention: Conventional CVC
Number of subjects: 172
Study 16969361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily and Metformin 500 mg three times daily
Number of subjects: 91
Study 16969361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug therapy)
Number of subjects: 91
Study 18245148 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (an IgG1‐TNF p75 receptor fusion protein), administered once weekly for 12 weeks
Number of subjects: 39
Study 18245148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15291188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb) solution (50 mg/kg or 35 mL for a 70-kg patient)
Number of subjects: 10
Study 15291188 — intervention group
Group type: COMPARATOR
Intervention: Hetastarch (control)
Number of subjects: 10
Study 11388055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening with clinical examination
Number of subjects: 0
Study 11388055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening without clinical examination
Number of subjects: 0
Study 11388055 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-designed observational studies
Number of subjects: 0
Study 11388055 — intervention group
Group type: COMPARATOR
Intervention: Randomized studies
Number of subjects: 0
Study 9519099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (600 mg/day)
Number of subjects: 28
Study 9519099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8368459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms once daily
Number of subjects: 218
Study 8368459 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate 5.2 mg four times daily
Number of subjects: 218
Study 3510125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen for 3 months
Number of subjects: 47
Study 3510125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3510125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 47
Study 11369073 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional simulation
Number of subjects: 86
Study 11369073 — intervention group
Group type: COMPARATOR
Intervention: Virtual simulation
Number of subjects: 86
Study 30198828 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast beta-glucan (900 mg daily for 16 weeks)
Number of subjects: 299
Study 30198828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 29444335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for cooperation with the teacher during clinical practicum
Number of subjects: 102
Study 29444335 — intervention group
Group type: COMPARATOR
Intervention: Standard cooperation (control group)
Number of subjects: 102
Study 26835603 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) 300 mg natalizumab
Number of subjects: 76
Study 26835603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 300 mg natalizumab
Number of subjects: 76
Study 26835603 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) 300 mg natalizumab
Number of subjects: 76
Study 26835603 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events across all groups
Number of subjects: 76
Study 26835603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamics (PD) response
Number of subjects: 76
Study 25409895 — intervention group
Group type: EXPERIMENTAL
Intervention: PRONTO simulation training
Number of subjects: 450